Metastatic malignant melanoma

12 trials 3 recruiting MedDRA PT
12 Registered trials
3 Recruiting
9 Unique sponsors
14 Unique IMPs
9 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 5
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 5
A Gastroenterology (ATC A) 1
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Checkpoint inhibitor (PD-1) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
RAF/BRAF inhibitor 1 substance
CDK inhibitor 1 substance
Kinase inhibitor 1 substance
Azole antifungal 1 substance
Phase III: 3 Phase II/III: 2 Phase II: 4 Phase I: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

3 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    NIVOLUMAB, RELATLIMAB
    2022-500967-11-00 11 countries 2023 n=423
    Recruiting
  • H e x a l AG Commercial
    IMP not specified
    2023-507865-24-00 11 countries 2025 n=302
    Ended
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended

Phase II/III

2 trials
  • Immunocore Limited Commercial
    PEMBROLIZUMAB; TEBENTAFUSP
    2022-502732-39-00 7 countries 2023 n=363 Orphan
    Recruiting
  • Universitaetsklinikum Regensburg Academic
    DICLOFENAC SODIUM; PANTOPRAZOLE
    2023-504191-26-00 1 country 2024 n=48
    Recruiting

Phase II

4 trials
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Novartis Pharma AG Commercial
    NAPORAFENIB; RIBOCICLIB; RINETERKIB; TRAMETINIB DIMETHYL SULFOXIDE
    2024-511934-11-00 4 countries 2021 n=53
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended
  • Institut De Cancerologie De L Ouest Academic
    FLUORODOPA (18F)
    2024-515850-26-00 1 country 2021 n=52
    Ended

Phase I

1 trial

Phase I (Other)

1 trial
  • Incyte Corp. Commercial
    INCB099280; IPILIMUMAB
    2023-503243-34-00 3 countries n=23
    Ended

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 3 Phase I (Other), Phase II, Phase I 0
Pfizer Inc. Commercial 2 Phase II, Phase III 0
Immunocore Limited Commercial 1 Phase II/III 1
Novartis Pharma AG Commercial 1 Phase II 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 1
H e x a l AG Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
Universitaetsklinikum Regensburg Academic 1 Phase II/III 1
Institut De Cancerologie De L Ouest Academic 1 Phase II 0
New trials by year
2021
3
2022
2
2023
4
2024
1
2025
1
← All indication landscapes